MORE VIDEOS
Explore more

Cancer

How is Advanced Bladder Cancer Treated?
How is Advanced Bladder Cancer Treated? administrator 1 Views • 2 years ago

This video explains how doctors treat advanced bladder cancer.
Non muscle invasive bladder cancer
Non muscle invasive bladder cancer administrator 0 Views • 2 years ago

North Bristol NHS Trust Patient Information Video re non muscle invasive bladder cancer
Management of High-Grade T1 Bladder Cancer
Management of High-Grade T1 Bladder Cancer administrator 1 Views • 2 years ago

Jeffrey M. Holzbeierlein, MD, Director of the Division of Urologic Oncology at the University of Kansas Hospital and Director of Clinical Research for the Urology Department at KUMC, talks about how to manage high-grade T1 bladder cancer (HGT1BC). He discusses 5-year progression rates of HGT1BC, pathological substratification of the disease, and risk calculators to estimate patient progression. Dr. Holzbeierlein concludes by discussing enhanced cystoscopy, the value of re-resection, and the importance of bacillus Calmette-Guerin (BCG) maintenance in HGT1BC.
Bladder Cancer Symptoms in Men | Cxbladder
Bladder Cancer Symptoms in Men | Cxbladder administrator 0 Views • 2 years ago

Bladder cancer is the sixth most common cancer among males globally, while men are four times more likely than women to be diagnosed with the disease during their lifetime. In this video we take a look at some of the symptoms of bladder cancer in men.

If you're concerned about bladder cancer, ask your doctor about Cxbladder

Cxbladder is a non-invasive genomic urine test that quickly and accurately detects or rules out bladder cancer in hematuria patients and those being monitored for bladder cancer recurrence. The test combines clinical risk factor markers with genetic information, measuring five biomarker genes to detect the presence or absence of bladder cancer.

Cxbladder gives you certainty, resolving diagnostic ambiguity and improving overall detection accuracy. Most patients experiencing hematuria or who are being monitored for bladder cancer recurrence do not have cancer. Cxbladder enables the accurate rule out of patients who do not have bladder cancer, reducing the need for further invasive tests.

With performance proven in 12 peer-reviewed studies, Cxbladder is trusted by over 1,800 US urologists in over 40,000 patients. The test is covered by Medicare and comes with the option of in-home sampling.

In New Zealand, Cxbladder is now accessible to 65% of the population via public healthcare. We offer the test to all other residents via our online shop.

Learn more bladder cancer and Cxbladder at: https://www.cxbladder.com

How Long Will You Live if You Have Bladder Cancer? by Dr. Cory Hugen - UCI Department of Urology
How Long Will You Live if You Have Bladder Cancer? by Dr. Cory Hugen - UCI Department of Urology administrator 1 Views • 2 years ago

Dr. Cory Hugen is dedicated to research and treatment for enlarged prostate and urologic cancers. His team operates in state-of-the-art facilities that are easily accessible in southern California to nearby Los Angeles, Riverside, and San Diego counties.

Dr. Hugen has presented his research at numerous national meetings and in many publications and book chapters. He is a member of the Society of Urologic Oncology, the Southwest Oncology Group, the American Urological Association, and the Alpha Omega Alpha Medical Honor Society. Additionally, he is a diplomate of the American Board of Urology.

https://coryhugenmd.com

Bladder Cancer - Pathology mini tutorial
Bladder Cancer - Pathology mini tutorial administrator 1 Views • 2 years ago

The types of bladder cancer with particular emphasis on the most common type (urothelial/transitional cell carcinoma). Other types of bladder cancer including adenocarcinoma, squamous cell carcinoma, sall cell carcinoma and sarcomas are mentioned. The risk factors are discussed including smoking and exposure to arylamines. Risk factors for squamous cell carcinoma (particularly schistosomiasis) and adenocarcinoma (cystitis glandularis and urachal remnant) are also covered. Gross and microscopic images are included such as micropapillary carcinoma, flat cis (carcinoma in situ) and squamous cell carcinoma.
Grading of bladder cancer is explained including the most recent WHO grading system. Growth patterns are covered including flat, papillary, solid and multifocal. This is part of a urological pathology playlist. The videos are particularly useful for pathology trainees and medical students. There are links to the urological pathology playlist and inverted papilloma of the bladder at the end of the video.
Epidemiology and presentation of bladder cancer 0:18
Gross image of bladder cancer 1:00
Different types of bladder cancer 1:08
Microscopic H&E image of bladder cancer 1:42
risk factors for bladder cancer 1:52
Grading and growth patterns of bladder cancer 2:44
Microscopic H&E image of grade 3 micropapillary bladder cancer 3:45
H&E of flat cis 3:58
Bladder squamous cell & small cell adenocarcinoma and adenocarcinoma risk factors 4:13
Squamous cell carcinoma H&E 4:50
Treatment of bladder cancer 5:16
RETAIN BLADDER: a risk-adapted approach to muscle invasive bladder cancer
RETAIN BLADDER: a risk-adapted approach to muscle invasive bladder cancer administrator 1 Views • 2 years ago

Daniel Geynisman, MD, Fox Chase Cancer Center, Philadelphia, PA, describes the interim analysis of the ongoing Phase II RETAIN BLADDER study, which aims to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer (MIBC). In this study, tumors from 71 patients with MIBC were sequenced for mutations, with the aim of identifying a specific subset of patients that could be spared cystectomy or chemoradiation following standard of care neoadjuvant chemotherapy, in order to improve quality of life while preserving oncologic outcomes in these patients. This interview took place during the 2021 Genitourinary Cancers Symposium.
Very high risk non-muscle-invasive bladder cancer (NMIBC) in the current landscape of NMIBC
Very high risk non-muscle-invasive bladder cancer (NMIBC) in the current landscape of NMIBC administrator 2 Views • 2 years ago

Dr. Mertens (NL) explains the position of very high risk non-muscle-invasive bladder cancer (NMIBC) in the current landscape of NMIBC.
The latest advancements in the treatment of bladder cancer
The latest advancements in the treatment of bladder cancer administrator 0 Views • 2 years ago

80% of bladder cancers can be managed from within the bladder, but in 20% of cases, the cancer may spread to the inner wall, and surgery becomes necessary. Due to the latest advancements in surgical techniques, robotic surgery makes this a safer option, with reduced recovery times, and better surgical outcomes.

Leading urological surgeon, Mr Philip Charlesworth explains all about how robotic surgery is used for the treatment of bladder cancer.

If you would like to book a consultation with Mr Charlesworth related to a diagnosis of bladder cancer, or any other urological conditions, you can do so here: https://www.topdoctors.co.uk/d....octor/philip-charles

✔ Follow us on Instagram: https://bit.ly/3fSrqXb
✔ Follow us on Facebook: https://bit.ly/3t5kGsW
✔ Follow us on Twitter: https://bit.ly/39TidKh

Targeted therapy effective for patients with advanced bladder cancer and specific gene mutations
Targeted therapy effective for patients with advanced bladder cancer and specific gene mutations administrator 1 Views • 2 years ago

An international Phase II clinical trial led by researchers at MD Anderson Cancer Center found that treatment with the FGFR inhibitor erdafitinib resulted in a 40% response rate for patients with metastatic bladder cancers marked by mutations in the FGFR3 gene.

Arlene Siefker-Radtke, M.D., principal investigator on the trial and professor of Genitourinary Medical Oncology at MD Anderson, discusses the importance of this clinical trial for patients with bladder and other urothelial cancers.

Request an appointment at MD Anderson by calling 1-877-632-6789 or online: https://my.mdanderson.org/RequestAppointment.

Showing 48 out of 49